Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3510910 | 0.87 | CTRB1 (0.40) | ATMCTSLAKT1CYP3A4 | |
| SCHEMBL12679251 | 0.84 | ATM (0.51) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL12679254 | 0.82 | ATM (0.45) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL12679216 | 0.78 | ATM (0.53) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL1529784 | 0.78 | CTRB1 (0.36) | ATMCTSLCYP3A4 | |
| SCHEMBL12767696 | 0.77 | ATM (0.52) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL13299998 | 0.77 | ATM (0.52) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL12679252 | 0.77 | ATM (0.43) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL12681387 | 0.76 | ATM (0.50) | ATMSYKAPPCTSSCTSK | |
| SCHEMBL12679268 | 0.76 | ATM (0.50) | ATMSYKAPPCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8946278-B2 | Inhibitors of AkT activity | GLAXOSMITHKLINE LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| WO-2008098104-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20160287561-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20110071182-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.